Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Amber Brown

Nurse Practitioner, Psychiatric/Mental Health Edmond, OK Nurse Practitioner

NPI 1558643866 CMS profile 10748579

2000 Sonoma Park Dr, Edmond, OK 73013

Open in the dashboard

General payments

$14,775

973 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amber Brown of Edmond, OK is reported in the CMS Open Payments database as having received $14,775 across 973 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,020 50
2024 General $4,218 282
2023 General $3,665 208
2022 General $3,008 209
2021 General $2,864 224

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amber Brown
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Amber Brown were reported at $1,020. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Amber Brown Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $2,864 $166 $54–$482 $132
2022 $3,008 $195 $66–$559 $149
2023 $3,665 $233 $82–$673 $160
2024 $4,218 $236 $84–$688 $164
2025 $1,020 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,231 182 payments
  2. ITI, Inc. $1,252 81 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $1,049 74 payments
  4. Alkermes, Inc. $944 53 payments
  5. Otsuka America Pharmaceutical, Inc. $875 70 payments
  6. Ironshore Pharmaceuticals Inc. $853 46 payments
  7. Axsome Therapeutics, Inc. $716 48 payments
  8. Neurocrine Biosciences, Inc. $704 49 payments
  9. Bausch Health US, LLC $677 41 payments
  10. Lundbeck LLC $645 40 payments
  11. Other $4,830 289 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,762 970 payments
  2. Education $13 3 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $1,980 161 payments
  2. CAPLYTA $1,181 78 payments
  3. TRINTELLIX $1,049 74 payments
  4. LYBALVI $874 48 payments
  5. REXULTI $688 65 payments
  6. APLENZIN $677 41 payments
  7. ABILIFY MAINTENA $666 44 payments
  8. ARISTADA Cns $659 37 payments
  9. ARISTADA Cns $659 37 payments
  10. INGREZZA $625 44 payments
  11. Other $10,187 597 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

537

Median for Nurse Practitioner: 389

Drug cost

$19,509

Median for Nurse Practitioner: $21,885

Branded share of claims

11.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belsomra Suvorexant Brand 21 $9,321
Vilazodone Hcl Generic 33 $2,386
Armodafinil Generic 11 $1,098
Duloxetine Hcl Generic 45 $941
Bupropion Xl Bupropion Hcl Brand 41 $893
Buspirone Hcl Generic 43 $638
Doxepin Hcl Generic 18 $624
Eszopiclone Generic 25 $568
Escitalopram Oxalate Generic 51 $536
Gabapentin Generic 28 $461

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
$473 — —
VRAYLAR
$439 — —
CAPLYTA
$388 — —
Qelbree
$375 — —
Auvelity
$258 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

973 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record